Jaguar Health's Crofelemer Shows Benefit for Intestinal Failure (IF) in Third Rare Congenital Enteropathy Disorder
The infant's results extend crofelemer's reported benefit to a third intestinal-failure-related congenital enteropathy under expanded access.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Jaguar Health (NASDAQ:JAGX) announced reduced parenteral support needs with investigational oral crofelemer in an infant with congenital sodium diarrhea.
The infant, whose disease involves a GUCY2C mutation, had approximately 15% lower daily parenteral support needs within the first several weeks. This intravenous nutrition and fluid support supplements inadequate intestinal absorption. Treatment under expanded access was well tolerated, with no significant clinical or laboratory abnormalities. Earlier pediatric findings showed weekly support needs normalized to body weight reduced by up to 48% in one microvillus inclusion disease (MVID) patient and up to 40% in two short bowel syndrome patients after more than 12 months. Jaguar plans an MVID approval application in mid-2027; its ongoing pivotal trial has completed enrollment.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.Jaguar plans a mid-2027 New Drug Application for crofelemer in MVID, including ongoing pivotal-trial results.
- Minor pointDaily parenteral support needs fell approximately 15% in the CSD infant within the first several weeks.
- Minor pointCSD infant treatment was well tolerated, with no significant clinical or laboratory abnormalities.
- Minor pointWeekly support needs normalized to body weight fell up to 48% in one MVID patient after >12 months.
- Minor pointWeekly support needs normalized to body weight fell up to 40% in two pediatric SBS-IF patients after >12 months.
2 minor points
- Minor pointLonger-term pediatric investigations reported no significant clinical or laboratory abnormalities during oral treatment for more than one year.
- Minor pointMVID pivotal trial enrollment is complete; the trial remains ongoing.
Negative
- Minor pointCSD findings cover one infant treated under expanded access for several weeks.
Key Figures
- Daily parenteral support reduction
- approximately 15%
- CSD infant patient, within the first several weeks
- Weekly parenteral support reduction
- up to 48%
- One MVID patient; normalized to body weight after >12 months of therapy
- Weekly parenteral support reduction
- up to 40%
- Two pediatric SBS-IF patients; normalized to body weight after >12 months of therapy
- Planned NDA filing
- mid-2027
- Crofelemer for MVID
Historical Context
-
Earlier pediatric reports described reduced weekly parenteral support needs after more than one year of oral dosing.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
gucy2c mutation medical
parenteral support medical
total parenteral nutrition medical
new drug application regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, CA / ACCESS Newswire / October 21, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Jaguar family company Napo Pharmaceuticals (Napo) has been continuing to provide the company's novel crofelemer powder for oral solution for several weeks for the treatment of intestinal failure (IF) in an infant patient with GUCY2C mutation resulting in congenital sodium diarrhea (CSD). Liquid oral crofelemer therapy is well tolerated by this patient and has demonstrated reduced needs for daily and weekly parenteral support (PS) with no significant clinical or laboratory abnormalities. CSD due to mutation of the GUCY2C gene is the third IF-related congenital enteropathy being evaluated under expanded access, in addition to pediatric microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF), for which crofelemer has demonstrated benefit in reducing weekly parenteral support needs normalized to body weight. The company plans to file a New Drug Application (NDA) for crofelemer for MVID in mid-2027 to obtain FDA approval based on data that will include results from an ongoing pivotal trial which has completed enrollment.
Patients with IF, including those with short bowel syndrome (SBS) or MVID, cannot orally absorb adequate nutrients, electrolytes and fluids, and require lifelong total parenteral nutrition (TPN) with or without supplemental intravenous fluids, which together comprise parenteral support (PS), for up to seven days per week and up to 20+ hours per day. While PS is supportive and lifesaving, it is associated with serious, sometimes fatal complications.
Pediatric CSD patients with GUCY2C mutation have a significant challenge for managing nutritional and electrolyte deficiencies, given the higher impact on growth and developmental needs. This pediatric patient with IF due to CSD requires significant daily PS, and liquid oral crofelemer therapy has reduced their daily PS needs by approximately
Napo remains sharply focused on its ongoing global development program for oral crofelemer as adjunctive therapy to PS for pediatric rare IF diseases. In June 2026, as announced, data was presented at the 58th Annual European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN) Meeting in Lille, France from ongoing investigational studies with oral liquid crofelemer in pediatric patients with IF due to MVID and SBS-IF. The results of ongoing investigations of liquid oral crofelemer formulations demonstrate substantial reductions in weekly PS needs as well as in PS normalized to body weight in pediatric IF patients dosed orally for more than one year, with no significant clinical or laboratory abnormalities. In one MVID patient, the weekly PS requirements normalized to body weight have been reduced by up to
About Crofelemer
Crofelemer is a novel, oral plant-based prescription medicine purified from the red bark sap, also referred to as "dragon's blood," of the Croton lechleri tree in the Amazon Rainforest. Napo Pharmaceuticals has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for indigenous communities.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. Jaguar family companies Napo Pharmaceuticals, Inc. (Napo) and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including microvillus inclusion disease and short bowel syndrome.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that the company may file an NDA (New Drug Application) with the U.S. Food and Drug Administration (FDA) for the MVID indication in mid-2027 based on data that will include results from an ongoing pivotal trial which has completed enrollment. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
hello@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Jaguar Health report for crofelemer in congenital sodium diarrhea?
An infant with intestinal failure caused by GUCY2C-related congenital sodium diarrhea had approximately 15% lower daily parenteral support needs within the first several weeks of oral crofelemer therapy. Treatment under expanded access was well tolerated, with no significant clinical or laboratory abnormalities.
When does Jaguar Health plan to seek FDA approval for crofelemer in MVID?
Jaguar plans to file a New Drug Application in mid-2027 seeking FDA approval for crofelemer in microvillus inclusion disease. The application is planned to include results from an ongoing pivotal trial that has completed enrollment.